No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
ATNM240517C5000
- 4.86
- +0.26+5.65%
15min DelayClose May 15 15:55 ET
4.86High4.86Low
4.86Open4.60Pre Close1 Volume319 Open Interest5.00Strike Price486.00Turnover1090.81%IV6.89%PremiumMay 17, 2024Expiry Date4.73Intrinsic Value100Multiplier2DDays to Expiry0.13Time Value100Contract SizeAmericanOptions Type0.8878Delta0.0235Gamma1.80Leverage Ratio-0.3816Theta0.0002Rho1.60Eff Leverage0.0014Vega
Intraday
- 5D
- 1D
News
Actinium to Host KOL Webinar to Discuss Iomab-ACT Commercial CAR T-Cell Therapy Trial Design, Objectives and Potential Market Opportunity
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs)...
Reported Earlier, Actinium To Present Improved Survival Outcomes In TP53 Positive Patients At The EHA 2024 and Long-Term Efficacy Results In Older Patients Receiving An Iomab-B Led Bone Marrow Transplant In The Phase 3 SIERRA Trial
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did not receive I
Actinium : Iomab-B Phase 3 Trial Results Show Significant Survival Benefit In High-Risk AML Patients
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the...
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Rec
NYSE American New 52-Week Highs And Lows
New Highs 5 COMPANY SYMBOL HIGH VOLUME ------- ------ ---- ------ Actinium Pharmaceuticals ATNM 9.99 307,312 Am
Express News | Actinium Pharmaceuticals Inc : Stephens Initiates Coverage With Overweight Rating; Price Target $25
Comments
$Actinium(ATNM.US$ Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did no...
- Median Overall Survival of 5.49 months observed in patients with a TP53 mutation receiving an Iomab-B led allogeneic bone marrow transplant compared to 1.66 months in patients that did no...
1
$Actinium(ATNM.US$
NEWS
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients wit...
NEWS
Actinium Announces Oral Presentation Detailing Improved Survival Outcomes in TP53 Positive Patients at the EHA 2024 Annual Congress and Presentation of Long-Term Efficacy Results in Older Patients Receiving an Iomab-B Led Bone Marrow Transplant in the Phase 3 SIERRA Trial
Actinium Pharmaceuticals announced that the Phase 3 SIERRA trial results of Iomab-B will be presented at the EHA 2024 Congress. The trial demonstrated significant survival benefits in older patients wit...
3
2
$Actinium(ATNM.US$
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
NEWS
Actinium Highlights Ability of Iomab-B to Overcome High-Risk TP53 Mutation Resulting in Significant Improvement in Overall Survival in Patients with Active Relapsed Refractory AML at the European Bone Marrow Transplant Annual Meeting
$Actinium(ATNM.US$ Actinium Pharmaceuticals Granted U.S. Patent #11844799: Method for Treating Cancer Using a BCL-2 Inhibitor in Conjunction With an Alpha-emitting Radioimmunotherapeutic![]()
3
2
$Actinium(ATNM.US$ Actinium to Highlight Broad Potential of Targeted Radiotherapies Iomab-B and Actimab-A for Relapsed or Refractory and Elderly Acute Myeloid Leukemia Patients at the 65th ASH Annual Meeting & Exposition
PR Newswire· 1 min ago![]()
PR Newswire· 1 min ago
Read more